Inflectra's Label Won't Depend On Continuing Study In IBD
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee members anxious about extrapolating Remicade's inflammatory bowel disease indications to biosimilar Inflectra wanted to wait for an ongoing trial, but FDA says idea misses the point of biosimilar pathway.
You may also be interested in...
Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences
Pink Sheet's Drug Review Profile reveals FDA's second biosimilar got hung up on product quality concerns that suggested potential differences between Celltrion's CT-P13 and its reference biologic, Janssen's infliximab.
Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences
Pink Sheet's Drug Review Profile reveals FDA's second biosimilar got hung up on product quality concerns that suggested potential differences between Celltrion's CT-P13 and its reference biologic, Janssen's infliximab.
How To Label A Biosimilar? Copy The Reference Product, FDA Told Sandoz
But agency had to weigh how presentation differences between Sandoz’s Zarxio and Amgen’s Neupogen, as well as Neupogen-specific safety information, should be reflected in the biosimilar’s labeling.